nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—PTGS2—urinary bladder cancer	0.353	1	CbGaD
Betamethasone—ABCB1—Mitomycin—urinary bladder cancer	0.0815	0.257	CbGbCtD
Betamethasone—PTGS2—Cisplatin—urinary bladder cancer	0.0517	0.163	CbGbCtD
Betamethasone—PTGS2—Etoposide—urinary bladder cancer	0.0507	0.16	CbGbCtD
Betamethasone—CYP3A4—Thiotepa—urinary bladder cancer	0.037	0.117	CbGbCtD
Betamethasone—ABCB1—Gemcitabine—urinary bladder cancer	0.0234	0.0739	CbGbCtD
Betamethasone—ABCB1—Cisplatin—urinary bladder cancer	0.017	0.0537	CbGbCtD
Betamethasone—ABCB1—Etoposide—urinary bladder cancer	0.0167	0.0527	CbGbCtD
Betamethasone—ABCB1—Doxorubicin—urinary bladder cancer	0.0114	0.036	CbGbCtD
Betamethasone—ABCB1—Methotrexate—urinary bladder cancer	0.0111	0.0348	CbGbCtD
Betamethasone—CYP3A4—Etoposide—urinary bladder cancer	0.01	0.0316	CbGbCtD
Betamethasone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00684	0.0216	CbGbCtD
Betamethasone—NR3C1—urine—urinary bladder cancer	0.00363	0.0599	CbGeAlD
Betamethasone—PLA2G1B—epithelium—urinary bladder cancer	0.0036	0.0594	CbGeAlD
Betamethasone—PLA2G1B—renal system—urinary bladder cancer	0.00334	0.0551	CbGeAlD
Betamethasone—CYP3A4—urine—urinary bladder cancer	0.00274	0.0453	CbGeAlD
Betamethasone—PLA2G1B—female reproductive system—urinary bladder cancer	0.00268	0.0442	CbGeAlD
Betamethasone—NR3C2—prostate gland—urinary bladder cancer	0.00243	0.0401	CbGeAlD
Betamethasone—PGR—prostate gland—urinary bladder cancer	0.00226	0.0372	CbGeAlD
Betamethasone—NR3C2—seminal vesicle—urinary bladder cancer	0.00205	0.0339	CbGeAlD
Betamethasone—CYP19A1—prostate gland—urinary bladder cancer	0.00203	0.0335	CbGeAlD
Betamethasone—NR3C2—smooth muscle tissue—urinary bladder cancer	0.00172	0.0284	CbGeAlD
Betamethasone—PGR—epithelium—urinary bladder cancer	0.00166	0.0274	CbGeAlD
Betamethasone—NR3C2—renal system—urinary bladder cancer	0.00165	0.0273	CbGeAlD
Betamethasone—NR3C2—urethra—urinary bladder cancer	0.00163	0.0268	CbGeAlD
Betamethasone—PGR—smooth muscle tissue—urinary bladder cancer	0.0016	0.0264	CbGeAlD
Betamethasone—NR3C2—female reproductive system—urinary bladder cancer	0.00133	0.0219	CbGeAlD
Betamethasone—NR3C1—prostate gland—urinary bladder cancer	0.0013	0.0215	CbGeAlD
Betamethasone—PGR—female reproductive system—urinary bladder cancer	0.00123	0.0203	CbGeAlD
Betamethasone—NR3C2—vagina—urinary bladder cancer	0.0012	0.0198	CbGeAlD
Betamethasone—PTGS2—prostate gland—urinary bladder cancer	0.00113	0.0186	CbGeAlD
Betamethasone—PGR—vagina—urinary bladder cancer	0.00111	0.0184	CbGeAlD
Betamethasone—CYP19A1—female reproductive system—urinary bladder cancer	0.00111	0.0183	CbGeAlD
Betamethasone—NR3C1—seminal vesicle—urinary bladder cancer	0.0011	0.0182	CbGeAlD
Betamethasone—NR3C1—epithelium—urinary bladder cancer	0.000957	0.0158	CbGeAlD
Betamethasone—PTGS2—seminal vesicle—urinary bladder cancer	0.000953	0.0157	CbGeAlD
Betamethasone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000922	0.0152	CbGeAlD
Betamethasone—NR3C1—renal system—urinary bladder cancer	0.000888	0.0146	CbGeAlD
Betamethasone—NR3C1—urethra—urinary bladder cancer	0.000872	0.0144	CbGeAlD
Betamethasone—PTGS2—epithelium—urinary bladder cancer	0.000828	0.0137	CbGeAlD
Betamethasone—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000798	0.0132	CbGeAlD
Betamethasone—NR3C2—lymph node—urinary bladder cancer	0.000775	0.0128	CbGeAlD
Betamethasone—PTGS2—renal system—urinary bladder cancer	0.000768	0.0127	CbGeAlD
Betamethasone—PTGS2—urethra—urinary bladder cancer	0.000755	0.0124	CbGeAlD
Betamethasone—PGR—lymph node—urinary bladder cancer	0.000721	0.0119	CbGeAlD
Betamethasone—NR3C1—female reproductive system—urinary bladder cancer	0.000711	0.0117	CbGeAlD
Betamethasone—ABCB1—prostate gland—urinary bladder cancer	0.000697	0.0115	CbGeAlD
Betamethasone—CYP3A4—renal system—urinary bladder cancer	0.000671	0.0111	CbGeAlD
Betamethasone—CYP19A1—lymph node—urinary bladder cancer	0.000649	0.0107	CbGeAlD
Betamethasone—NR3C1—vagina—urinary bladder cancer	0.000643	0.0106	CbGeAlD
Betamethasone—PTGS2—female reproductive system—urinary bladder cancer	0.000615	0.0102	CbGeAlD
Betamethasone—ABCB1—seminal vesicle—urinary bladder cancer	0.00059	0.00973	CbGeAlD
Betamethasone—PTGS2—vagina—urinary bladder cancer	0.000556	0.00918	CbGeAlD
Betamethasone—CYP3A4—female reproductive system—urinary bladder cancer	0.000538	0.00887	CbGeAlD
Betamethasone—ABCB1—epithelium—urinary bladder cancer	0.000512	0.00845	CbGeAlD
Betamethasone—ABCB1—renal system—urinary bladder cancer	0.000475	0.00784	CbGeAlD
Betamethasone—ABCB1—urethra—urinary bladder cancer	0.000467	0.0077	CbGeAlD
Betamethasone—NR3C1—lymph node—urinary bladder cancer	0.000416	0.00686	CbGeAlD
Betamethasone—ABCB1—female reproductive system—urinary bladder cancer	0.000381	0.00628	CbGeAlD
Betamethasone—PTGS2—lymph node—urinary bladder cancer	0.00036	0.00594	CbGeAlD
Betamethasone—ABCB1—vagina—urinary bladder cancer	0.000344	0.00568	CbGeAlD
Betamethasone—ABCB1—lymph node—urinary bladder cancer	0.000223	0.00367	CbGeAlD
Betamethasone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000155	0.000841	CcSEcCtD
Betamethasone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000155	0.000838	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000154	0.000836	CcSEcCtD
Betamethasone—Dry skin—Epirubicin—urinary bladder cancer	0.000154	0.000833	CcSEcCtD
Betamethasone—Insomnia—Fluorouracil—urinary bladder cancer	0.000153	0.00083	CcSEcCtD
Betamethasone—Anorexia—Cisplatin—urinary bladder cancer	0.000153	0.000829	CcSEcCtD
Betamethasone—Affect lability—Doxorubicin—urinary bladder cancer	0.000153	0.000827	CcSEcCtD
Betamethasone—Migraine—Doxorubicin—urinary bladder cancer	0.000153	0.000827	CcSEcCtD
Betamethasone—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000153	0.000827	CcSEcCtD
Betamethasone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000152	0.000824	CcSEcCtD
Betamethasone—Discomfort—Etoposide—urinary bladder cancer	0.000151	0.000821	CcSEcCtD
Betamethasone—Hypotension—Cisplatin—urinary bladder cancer	0.00015	0.000813	CcSEcCtD
Betamethasone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00015	0.000811	CcSEcCtD
Betamethasone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000149	0.000807	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000149	0.000805	CcSEcCtD
Betamethasone—Fatigue—Gemcitabine—urinary bladder cancer	0.000148	0.000804	CcSEcCtD
Betamethasone—Muscular weakness—Epirubicin—urinary bladder cancer	0.000148	0.000801	CcSEcCtD
Betamethasone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000147	0.000799	CcSEcCtD
Betamethasone—Pain—Gemcitabine—urinary bladder cancer	0.000147	0.000798	CcSEcCtD
Betamethasone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000147	0.000797	CcSEcCtD
Betamethasone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000147	0.000797	CcSEcCtD
Betamethasone—Mood swings—Doxorubicin—urinary bladder cancer	0.000147	0.000796	CcSEcCtD
Betamethasone—Asthenia—Thiotepa—urinary bladder cancer	0.000147	0.000796	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000146	0.000792	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000146	0.000792	CcSEcCtD
Betamethasone—Infection—Etoposide—urinary bladder cancer	0.000146	0.000791	CcSEcCtD
Betamethasone—Pruritus—Thiotepa—urinary bladder cancer	0.000145	0.000785	CcSEcCtD
Betamethasone—Pain—Fluorouracil—urinary bladder cancer	0.000145	0.000784	CcSEcCtD
Betamethasone—Paraesthesia—Cisplatin—urinary bladder cancer	0.000144	0.000781	CcSEcCtD
Betamethasone—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000144	0.00078	CcSEcCtD
Betamethasone—Tachycardia—Etoposide—urinary bladder cancer	0.000143	0.000777	CcSEcCtD
Betamethasone—Dry skin—Doxorubicin—urinary bladder cancer	0.000142	0.000771	CcSEcCtD
Betamethasone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000142	0.00077	CcSEcCtD
Betamethasone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000142	0.000769	CcSEcCtD
Betamethasone—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000141	0.000765	CcSEcCtD
Betamethasone—Anorexia—Etoposide—urinary bladder cancer	0.00014	0.000759	CcSEcCtD
Betamethasone—Diarrhoea—Thiotepa—urinary bladder cancer	0.00014	0.000759	CcSEcCtD
Betamethasone—Decreased appetite—Cisplatin—urinary bladder cancer	0.000139	0.000756	CcSEcCtD
Betamethasone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000139	0.000756	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000139	0.000751	CcSEcCtD
Betamethasone—Hypotension—Etoposide—urinary bladder cancer	0.000137	0.000744	CcSEcCtD
Betamethasone—Pain—Cisplatin—urinary bladder cancer	0.000137	0.000744	CcSEcCtD
Betamethasone—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000137	0.000741	CcSEcCtD
Betamethasone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000136	0.000737	CcSEcCtD
Betamethasone—Dizziness—Thiotepa—urinary bladder cancer	0.000135	0.000733	CcSEcCtD
Betamethasone—Urticaria—Fluorouracil—urinary bladder cancer	0.000134	0.000729	CcSEcCtD
Betamethasone—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000134	0.000727	CcSEcCtD
Betamethasone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000134	0.000725	CcSEcCtD
Betamethasone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000132	0.000717	CcSEcCtD
Betamethasone—Paraesthesia—Etoposide—urinary bladder cancer	0.000132	0.000715	CcSEcCtD
Betamethasone—Weight increased—Epirubicin—urinary bladder cancer	0.000132	0.000715	CcSEcCtD
Betamethasone—Weight decreased—Epirubicin—urinary bladder cancer	0.000131	0.00071	CcSEcCtD
Betamethasone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000131	0.000708	CcSEcCtD
Betamethasone—Vomiting—Thiotepa—urinary bladder cancer	0.00013	0.000705	CcSEcCtD
Betamethasone—Rash—Thiotepa—urinary bladder cancer	0.000129	0.000699	CcSEcCtD
Betamethasone—Dermatitis—Thiotepa—urinary bladder cancer	0.000129	0.000699	CcSEcCtD
Betamethasone—Headache—Thiotepa—urinary bladder cancer	0.000128	0.000695	CcSEcCtD
Betamethasone—Decreased appetite—Etoposide—urinary bladder cancer	0.000128	0.000692	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000127	0.000688	CcSEcCtD
Betamethasone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000127	0.000687	CcSEcCtD
Betamethasone—Fatigue—Etoposide—urinary bladder cancer	0.000127	0.000687	CcSEcCtD
Betamethasone—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000127	0.000686	CcSEcCtD
Betamethasone—Pain—Etoposide—urinary bladder cancer	0.000126	0.000681	CcSEcCtD
Betamethasone—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000126	0.000681	CcSEcCtD
Betamethasone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000125	0.000675	CcSEcCtD
Betamethasone—Haemorrhage—Methotrexate—urinary bladder cancer	0.000124	0.000672	CcSEcCtD
Betamethasone—Asthenia—Gemcitabine—urinary bladder cancer	0.000123	0.000669	CcSEcCtD
Betamethasone—Weight increased—Doxorubicin—urinary bladder cancer	0.000122	0.000661	CcSEcCtD
Betamethasone—Pruritus—Gemcitabine—urinary bladder cancer	0.000122	0.00066	CcSEcCtD
Betamethasone—Nausea—Thiotepa—urinary bladder cancer	0.000122	0.000659	CcSEcCtD
Betamethasone—Weight decreased—Doxorubicin—urinary bladder cancer	0.000121	0.000657	CcSEcCtD
Betamethasone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000121	0.000656	CcSEcCtD
Betamethasone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000121	0.000655	CcSEcCtD
Betamethasone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00012	0.000651	CcSEcCtD
Betamethasone—Pruritus—Fluorouracil—urinary bladder cancer	0.00012	0.000649	CcSEcCtD
Betamethasone—Visual impairment—Methotrexate—urinary bladder cancer	0.000119	0.000647	CcSEcCtD
Betamethasone—Bradycardia—Epirubicin—urinary bladder cancer	0.000118	0.00064	CcSEcCtD
Betamethasone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000118	0.000638	CcSEcCtD
Betamethasone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000117	0.000635	CcSEcCtD
Betamethasone—Urticaria—Etoposide—urinary bladder cancer	0.000117	0.000633	CcSEcCtD
Betamethasone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000117	0.000632	CcSEcCtD
Betamethasone—Abdominal pain—Etoposide—urinary bladder cancer	0.000116	0.00063	CcSEcCtD
Betamethasone—Body temperature increased—Etoposide—urinary bladder cancer	0.000116	0.00063	CcSEcCtD
Betamethasone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000116	0.00063	CcSEcCtD
Betamethasone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000116	0.000629	CcSEcCtD
Betamethasone—Eye disorder—Methotrexate—urinary bladder cancer	0.000116	0.000628	CcSEcCtD
Betamethasone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000116	0.000628	CcSEcCtD
Betamethasone—Asthenia—Cisplatin—urinary bladder cancer	0.000115	0.000624	CcSEcCtD
Betamethasone—Angiopathy—Methotrexate—urinary bladder cancer	0.000112	0.000609	CcSEcCtD
Betamethasone—Dizziness—Fluorouracil—urinary bladder cancer	0.000112	0.000607	CcSEcCtD
Betamethasone—Visual impairment—Epirubicin—urinary bladder cancer	0.000112	0.000606	CcSEcCtD
Betamethasone—Diarrhoea—Cisplatin—urinary bladder cancer	0.00011	0.000595	CcSEcCtD
Betamethasone—Alopecia—Methotrexate—urinary bladder cancer	0.000109	0.000593	CcSEcCtD
Betamethasone—Vomiting—Gemcitabine—urinary bladder cancer	0.000109	0.000593	CcSEcCtD
Betamethasone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000109	0.000592	CcSEcCtD
Betamethasone—Rash—Gemcitabine—urinary bladder cancer	0.000109	0.000588	CcSEcCtD
Betamethasone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000108	0.000588	CcSEcCtD
Betamethasone—Eye disorder—Epirubicin—urinary bladder cancer	0.000108	0.000587	CcSEcCtD
Betamethasone—Erythema—Methotrexate—urinary bladder cancer	0.000108	0.000585	CcSEcCtD
Betamethasone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000108	0.000585	CcSEcCtD
Betamethasone—Headache—Gemcitabine—urinary bladder cancer	0.000108	0.000584	CcSEcCtD
Betamethasone—Vomiting—Fluorouracil—urinary bladder cancer	0.000108	0.000583	CcSEcCtD
Betamethasone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000107	0.000582	CcSEcCtD
Betamethasone—Rash—Fluorouracil—urinary bladder cancer	0.000107	0.000578	CcSEcCtD
Betamethasone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000107	0.000578	CcSEcCtD
Betamethasone—Headache—Fluorouracil—urinary bladder cancer	0.000106	0.000575	CcSEcCtD
Betamethasone—Asthenia—Etoposide—urinary bladder cancer	0.000105	0.000572	CcSEcCtD
Betamethasone—Angiopathy—Epirubicin—urinary bladder cancer	0.000105	0.00057	CcSEcCtD
Betamethasone—Pruritus—Etoposide—urinary bladder cancer	0.000104	0.000564	CcSEcCtD
Betamethasone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000104	0.000561	CcSEcCtD
Betamethasone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000103	0.00056	CcSEcCtD
Betamethasone—Alopecia—Epirubicin—urinary bladder cancer	0.000102	0.000555	CcSEcCtD
Betamethasone—Nausea—Gemcitabine—urinary bladder cancer	0.000102	0.000554	CcSEcCtD
Betamethasone—Vomiting—Cisplatin—urinary bladder cancer	0.000102	0.000553	CcSEcCtD
Betamethasone—Rash—Cisplatin—urinary bladder cancer	0.000101	0.000548	CcSEcCtD
Betamethasone—Dermatitis—Cisplatin—urinary bladder cancer	0.000101	0.000548	CcSEcCtD
Betamethasone—Erythema—Epirubicin—urinary bladder cancer	0.000101	0.000547	CcSEcCtD
Betamethasone—Diarrhoea—Etoposide—urinary bladder cancer	0.000101	0.000545	CcSEcCtD
Betamethasone—Nausea—Fluorouracil—urinary bladder cancer	0.000101	0.000545	CcSEcCtD
Betamethasone—Eye disorder—Doxorubicin—urinary bladder cancer	0.0001	0.000543	CcSEcCtD
Betamethasone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.0001	0.000542	CcSEcCtD
Betamethasone—Angiopathy—Doxorubicin—urinary bladder cancer	9.73e-05	0.000528	CcSEcCtD
Betamethasone—Malaise—Methotrexate—urinary bladder cancer	9.73e-05	0.000527	CcSEcCtD
Betamethasone—Dizziness—Etoposide—urinary bladder cancer	9.72e-05	0.000527	CcSEcCtD
Betamethasone—Vertigo—Methotrexate—urinary bladder cancer	9.69e-05	0.000525	CcSEcCtD
Betamethasone—Arrhythmia—Doxorubicin—urinary bladder cancer	9.59e-05	0.00052	CcSEcCtD
Betamethasone—Nausea—Cisplatin—urinary bladder cancer	9.53e-05	0.000516	CcSEcCtD
Betamethasone—Alopecia—Doxorubicin—urinary bladder cancer	9.48e-05	0.000514	CcSEcCtD
Betamethasone—Ill-defined disorder—Epirubicin—urinary bladder cancer	9.37e-05	0.000508	CcSEcCtD
Betamethasone—Convulsion—Methotrexate—urinary bladder cancer	9.35e-05	0.000507	CcSEcCtD
Betamethasone—Vomiting—Etoposide—urinary bladder cancer	9.34e-05	0.000506	CcSEcCtD
Betamethasone—Erythema—Doxorubicin—urinary bladder cancer	9.34e-05	0.000506	CcSEcCtD
Betamethasone—Rash—Etoposide—urinary bladder cancer	9.27e-05	0.000502	CcSEcCtD
Betamethasone—Dermatitis—Etoposide—urinary bladder cancer	9.26e-05	0.000502	CcSEcCtD
Betamethasone—Headache—Etoposide—urinary bladder cancer	9.21e-05	0.000499	CcSEcCtD
Betamethasone—Myalgia—Methotrexate—urinary bladder cancer	9.18e-05	0.000498	CcSEcCtD
Betamethasone—Malaise—Epirubicin—urinary bladder cancer	9.1e-05	0.000493	CcSEcCtD
Betamethasone—Discomfort—Methotrexate—urinary bladder cancer	9.07e-05	0.000492	CcSEcCtD
Betamethasone—Vertigo—Epirubicin—urinary bladder cancer	9.07e-05	0.000492	CcSEcCtD
Betamethasone—Syncope—Epirubicin—urinary bladder cancer	9.05e-05	0.000491	CcSEcCtD
Betamethasone—Loss of consciousness—Epirubicin—urinary bladder cancer	8.87e-05	0.000481	CcSEcCtD
Betamethasone—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.8e-05	0.000477	CcSEcCtD
Betamethasone—Convulsion—Epirubicin—urinary bladder cancer	8.75e-05	0.000474	CcSEcCtD
Betamethasone—Infection—Methotrexate—urinary bladder cancer	8.75e-05	0.000474	CcSEcCtD
Betamethasone—Nausea—Etoposide—urinary bladder cancer	8.73e-05	0.000473	CcSEcCtD
Betamethasone—Hypertension—Epirubicin—urinary bladder cancer	8.72e-05	0.000472	CcSEcCtD
Betamethasone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.67e-05	0.00047	CcSEcCtD
Betamethasone—Nervous system disorder—Methotrexate—urinary bladder cancer	8.63e-05	0.000468	CcSEcCtD
Betamethasone—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.62e-05	0.000467	CcSEcCtD
Betamethasone—Myalgia—Epirubicin—urinary bladder cancer	8.59e-05	0.000466	CcSEcCtD
Betamethasone—Anxiety—Epirubicin—urinary bladder cancer	8.56e-05	0.000464	CcSEcCtD
Betamethasone—Hyperhidrosis—Methotrexate—urinary bladder cancer	8.51e-05	0.000461	CcSEcCtD
Betamethasone—Discomfort—Epirubicin—urinary bladder cancer	8.49e-05	0.00046	CcSEcCtD
Betamethasone—Malaise—Doxorubicin—urinary bladder cancer	8.42e-05	0.000457	CcSEcCtD
Betamethasone—Vertigo—Doxorubicin—urinary bladder cancer	8.39e-05	0.000455	CcSEcCtD
Betamethasone—Anorexia—Methotrexate—urinary bladder cancer	8.39e-05	0.000455	CcSEcCtD
Betamethasone—Syncope—Doxorubicin—urinary bladder cancer	8.38e-05	0.000454	CcSEcCtD
Betamethasone—Anaphylactic shock—Epirubicin—urinary bladder cancer	8.24e-05	0.000447	CcSEcCtD
Betamethasone—Oedema—Epirubicin—urinary bladder cancer	8.24e-05	0.000447	CcSEcCtD
Betamethasone—Hypotension—Methotrexate—urinary bladder cancer	8.23e-05	0.000446	CcSEcCtD
Betamethasone—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.21e-05	0.000445	CcSEcCtD
Betamethasone—Infection—Epirubicin—urinary bladder cancer	8.18e-05	0.000444	CcSEcCtD
Betamethasone—Shock—Epirubicin—urinary bladder cancer	8.11e-05	0.000439	CcSEcCtD
Betamethasone—Convulsion—Doxorubicin—urinary bladder cancer	8.09e-05	0.000439	CcSEcCtD
Betamethasone—Nervous system disorder—Epirubicin—urinary bladder cancer	8.08e-05	0.000438	CcSEcCtD
Betamethasone—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.07e-05	0.000437	CcSEcCtD
Betamethasone—Hypertension—Doxorubicin—urinary bladder cancer	8.06e-05	0.000437	CcSEcCtD
Betamethasone—Tachycardia—Epirubicin—urinary bladder cancer	8.04e-05	0.000436	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	8.02e-05	0.000435	CcSEcCtD
Betamethasone—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.96e-05	0.000432	CcSEcCtD
Betamethasone—Insomnia—Methotrexate—urinary bladder cancer	7.96e-05	0.000432	CcSEcCtD
Betamethasone—Myalgia—Doxorubicin—urinary bladder cancer	7.95e-05	0.000431	CcSEcCtD
Betamethasone—Anxiety—Doxorubicin—urinary bladder cancer	7.92e-05	0.00043	CcSEcCtD
Betamethasone—Paraesthesia—Methotrexate—urinary bladder cancer	7.91e-05	0.000428	CcSEcCtD
Betamethasone—Discomfort—Doxorubicin—urinary bladder cancer	7.86e-05	0.000426	CcSEcCtD
Betamethasone—Anorexia—Epirubicin—urinary bladder cancer	7.85e-05	0.000426	CcSEcCtD
Betamethasone—Dyspepsia—Methotrexate—urinary bladder cancer	7.75e-05	0.00042	CcSEcCtD
Betamethasone—Hypotension—Epirubicin—urinary bladder cancer	7.7e-05	0.000417	CcSEcCtD
Betamethasone—Decreased appetite—Methotrexate—urinary bladder cancer	7.65e-05	0.000415	CcSEcCtD
Betamethasone—Oedema—Doxorubicin—urinary bladder cancer	7.62e-05	0.000413	CcSEcCtD
Betamethasone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.62e-05	0.000413	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.6e-05	0.000412	CcSEcCtD
Betamethasone—Fatigue—Methotrexate—urinary bladder cancer	7.59e-05	0.000411	CcSEcCtD
Betamethasone—Infection—Doxorubicin—urinary bladder cancer	7.57e-05	0.00041	CcSEcCtD
Betamethasone—Pain—Methotrexate—urinary bladder cancer	7.53e-05	0.000408	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.51e-05	0.000407	CcSEcCtD
Betamethasone—Shock—Doxorubicin—urinary bladder cancer	7.5e-05	0.000406	CcSEcCtD
Betamethasone—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.48e-05	0.000405	CcSEcCtD
Betamethasone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.46e-05	0.000405	CcSEcCtD
Betamethasone—Insomnia—Epirubicin—urinary bladder cancer	7.45e-05	0.000404	CcSEcCtD
Betamethasone—Tachycardia—Doxorubicin—urinary bladder cancer	7.44e-05	0.000403	CcSEcCtD
Betamethasone—Paraesthesia—Epirubicin—urinary bladder cancer	7.4e-05	0.000401	CcSEcCtD
Betamethasone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7.37e-05	0.000399	CcSEcCtD
Betamethasone—Anorexia—Doxorubicin—urinary bladder cancer	7.27e-05	0.000394	CcSEcCtD
Betamethasone—Feeling abnormal—Methotrexate—urinary bladder cancer	7.25e-05	0.000393	CcSEcCtD
Betamethasone—Dyspepsia—Epirubicin—urinary bladder cancer	7.25e-05	0.000393	CcSEcCtD
Betamethasone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.2e-05	0.00039	CcSEcCtD
Betamethasone—Decreased appetite—Epirubicin—urinary bladder cancer	7.16e-05	0.000388	CcSEcCtD
Betamethasone—Hypotension—Doxorubicin—urinary bladder cancer	7.12e-05	0.000386	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.11e-05	0.000386	CcSEcCtD
Betamethasone—Fatigue—Epirubicin—urinary bladder cancer	7.1e-05	0.000385	CcSEcCtD
Betamethasone—Pain—Epirubicin—urinary bladder cancer	7.05e-05	0.000382	CcSEcCtD
Betamethasone—Urticaria—Methotrexate—urinary bladder cancer	6.99e-05	0.000379	CcSEcCtD
Betamethasone—Abdominal pain—Methotrexate—urinary bladder cancer	6.96e-05	0.000377	CcSEcCtD
Betamethasone—Body temperature increased—Methotrexate—urinary bladder cancer	6.96e-05	0.000377	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.95e-05	0.000376	CcSEcCtD
Betamethasone—Insomnia—Doxorubicin—urinary bladder cancer	6.89e-05	0.000374	CcSEcCtD
Betamethasone—Paraesthesia—Doxorubicin—urinary bladder cancer	6.85e-05	0.000371	CcSEcCtD
Betamethasone—Feeling abnormal—Epirubicin—urinary bladder cancer	6.79e-05	0.000368	CcSEcCtD
Betamethasone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.74e-05	0.000365	CcSEcCtD
Betamethasone—Dyspepsia—Doxorubicin—urinary bladder cancer	6.71e-05	0.000364	CcSEcCtD
Betamethasone—Decreased appetite—Doxorubicin—urinary bladder cancer	6.63e-05	0.000359	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.58e-05	0.000357	CcSEcCtD
Betamethasone—Fatigue—Doxorubicin—urinary bladder cancer	6.57e-05	0.000356	CcSEcCtD
Betamethasone—Urticaria—Epirubicin—urinary bladder cancer	6.54e-05	0.000355	CcSEcCtD
Betamethasone—Pain—Doxorubicin—urinary bladder cancer	6.52e-05	0.000353	CcSEcCtD
Betamethasone—Abdominal pain—Epirubicin—urinary bladder cancer	6.51e-05	0.000353	CcSEcCtD
Betamethasone—Body temperature increased—Epirubicin—urinary bladder cancer	6.51e-05	0.000353	CcSEcCtD
Betamethasone—Asthenia—Methotrexate—urinary bladder cancer	6.32e-05	0.000342	CcSEcCtD
Betamethasone—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.28e-05	0.00034	CcSEcCtD
Betamethasone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.23e-05	0.000338	CcSEcCtD
Betamethasone—Pruritus—Methotrexate—urinary bladder cancer	6.23e-05	0.000338	CcSEcCtD
Betamethasone—Urticaria—Doxorubicin—urinary bladder cancer	6.06e-05	0.000328	CcSEcCtD
Betamethasone—Body temperature increased—Doxorubicin—urinary bladder cancer	6.03e-05	0.000327	CcSEcCtD
Betamethasone—Abdominal pain—Doxorubicin—urinary bladder cancer	6.03e-05	0.000327	CcSEcCtD
Betamethasone—Diarrhoea—Methotrexate—urinary bladder cancer	6.02e-05	0.000326	CcSEcCtD
Betamethasone—Asthenia—Epirubicin—urinary bladder cancer	5.91e-05	0.00032	CcSEcCtD
Betamethasone—Pruritus—Epirubicin—urinary bladder cancer	5.83e-05	0.000316	CcSEcCtD
Betamethasone—Dizziness—Methotrexate—urinary bladder cancer	5.82e-05	0.000316	CcSEcCtD
Betamethasone—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	5.76e-05	0.000685	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	5.75e-05	0.000684	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.72e-05	0.000681	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	5.66e-05	0.000674	CbGpPWpGaD
Betamethasone—Diarrhoea—Epirubicin—urinary bladder cancer	5.64e-05	0.000306	CcSEcCtD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.6e-05	0.000667	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—GPX1—urinary bladder cancer	5.6e-05	0.000666	CbGpPWpGaD
Betamethasone—Vomiting—Methotrexate—urinary bladder cancer	5.6e-05	0.000303	CcSEcCtD
Betamethasone—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	5.59e-05	0.000665	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	5.58e-05	0.000664	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	5.58e-05	0.000664	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	5.56e-05	0.000662	CbGpPWpGaD
Betamethasone—Rash—Methotrexate—urinary bladder cancer	5.55e-05	0.000301	CcSEcCtD
Betamethasone—Dermatitis—Methotrexate—urinary bladder cancer	5.55e-05	0.000301	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	5.54e-05	0.000659	CbGpPWpGaD
Betamethasone—Headache—Methotrexate—urinary bladder cancer	5.52e-05	0.000299	CcSEcCtD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.5e-05	0.000655	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—ERCC2—urinary bladder cancer	5.5e-05	0.000654	CbGpPWpGaD
Betamethasone—Asthenia—Doxorubicin—urinary bladder cancer	5.47e-05	0.000296	CcSEcCtD
Betamethasone—Dizziness—Epirubicin—urinary bladder cancer	5.45e-05	0.000295	CcSEcCtD
Betamethasone—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	5.43e-05	0.000646	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—ESR2—urinary bladder cancer	5.43e-05	0.000646	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—ESR1—urinary bladder cancer	5.4e-05	0.000643	CbGpPWpGaD
Betamethasone—Pruritus—Doxorubicin—urinary bladder cancer	5.39e-05	0.000292	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.28e-05	0.000629	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTO2—urinary bladder cancer	5.27e-05	0.000627	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NAT1—urinary bladder cancer	5.27e-05	0.000627	CbGpPWpGaD
Betamethasone—NR3C1—Adipogenesis—TNF—urinary bladder cancer	5.24e-05	0.000624	CbGpPWpGaD
Betamethasone—Vomiting—Epirubicin—urinary bladder cancer	5.24e-05	0.000284	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	5.23e-05	0.000623	CbGpPWpGaD
Betamethasone—Nausea—Methotrexate—urinary bladder cancer	5.23e-05	0.000283	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.22e-05	0.000621	CbGpPWpGaD
Betamethasone—Diarrhoea—Doxorubicin—urinary bladder cancer	5.22e-05	0.000283	CcSEcCtD
Betamethasone—Rash—Epirubicin—urinary bladder cancer	5.19e-05	0.000282	CcSEcCtD
Betamethasone—Dermatitis—Epirubicin—urinary bladder cancer	5.19e-05	0.000281	CcSEcCtD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.19e-05	0.000617	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—MTHFR—urinary bladder cancer	5.17e-05	0.000615	CbGpPWpGaD
Betamethasone—Headache—Epirubicin—urinary bladder cancer	5.16e-05	0.00028	CcSEcCtD
Betamethasone—Dizziness—Doxorubicin—urinary bladder cancer	5.04e-05	0.000273	CcSEcCtD
Betamethasone—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	5.03e-05	0.000598	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—PPARG—urinary bladder cancer	4.93e-05	0.000587	CbGpPWpGaD
Betamethasone—PTGS2—Disease—SLC19A1—urinary bladder cancer	4.9e-05	0.000583	CbGpPWpGaD
Betamethasone—Nausea—Epirubicin—urinary bladder cancer	4.89e-05	0.000265	CcSEcCtD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.88e-05	0.00058	CbGpPWpGaD
Betamethasone—Vomiting—Doxorubicin—urinary bladder cancer	4.85e-05	0.000263	CcSEcCtD
Betamethasone—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	4.82e-05	0.000574	CbGpPWpGaD
Betamethasone—Rash—Doxorubicin—urinary bladder cancer	4.81e-05	0.000261	CcSEcCtD
Betamethasone—Dermatitis—Doxorubicin—urinary bladder cancer	4.8e-05	0.00026	CcSEcCtD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.79e-05	0.000571	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—TYMP—urinary bladder cancer	4.78e-05	0.000569	CbGpPWpGaD
Betamethasone—Headache—Doxorubicin—urinary bladder cancer	4.78e-05	0.000259	CcSEcCtD
Betamethasone—PTGS2—Disease—PRSS3—urinary bladder cancer	4.77e-05	0.000568	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	4.75e-05	0.000565	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—CREBBP—urinary bladder cancer	4.74e-05	0.000564	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.7e-05	0.00056	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	4.65e-05	0.000553	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	4.61e-05	0.000548	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.59e-05	0.000546	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HDAC4—urinary bladder cancer	4.55e-05	0.000542	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	4.53e-05	0.000539	CbGpPWpGaD
Betamethasone—Nausea—Doxorubicin—urinary bladder cancer	4.53e-05	0.000245	CcSEcCtD
Betamethasone—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	4.51e-05	0.000536	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.42e-05	0.000526	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	4.34e-05	0.000517	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—NAT2—urinary bladder cancer	4.32e-05	0.000515	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.31e-05	0.000513	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	4.29e-05	0.000511	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.29e-05	0.000511	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.27e-05	0.000508	CbGpPWpGaD
Betamethasone—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	4.19e-05	0.000499	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PPARG—urinary bladder cancer	4.19e-05	0.000499	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—NCOR1—urinary bladder cancer	4.19e-05	0.000499	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—RBX1—urinary bladder cancer	4.18e-05	0.000497	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	4.1e-05	0.000488	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—CREBBP—urinary bladder cancer	4.03e-05	0.000479	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4e-05	0.000476	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.97e-05	0.000472	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	3.95e-05	0.00047	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	3.94e-05	0.000469	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—ERCC2—urinary bladder cancer	3.94e-05	0.000469	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TSC1—urinary bladder cancer	3.93e-05	0.000468	CbGpPWpGaD
Betamethasone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.91e-05	0.000465	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.91e-05	0.000465	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	3.78e-05	0.00045	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.78e-05	0.00045	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.77e-05	0.000449	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.74e-05	0.000446	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—JAG1—urinary bladder cancer	3.74e-05	0.000445	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.74e-05	0.000445	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.74e-05	0.000445	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—RRM2—urinary bladder cancer	3.73e-05	0.000444	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.7e-05	0.00044	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.64e-05	0.000434	CbGpPWpGaD
Betamethasone—PTGS2—Disease—LIG1—urinary bladder cancer	3.62e-05	0.00043	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	3.6e-05	0.000429	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	3.6e-05	0.000428	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.6e-05	0.000428	CbGpPWpGaD
Betamethasone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.59e-05	0.000428	CbGpPWpGaD
Betamethasone—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	3.55e-05	0.000423	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.5e-05	0.000416	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	3.46e-05	0.000412	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ENO2—urinary bladder cancer	3.46e-05	0.000411	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	3.46e-05	0.000411	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.44e-05	0.000409	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.42e-05	0.000407	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	3.35e-05	0.000399	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.3e-05	0.000393	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PTGS2—urinary bladder cancer	3.3e-05	0.000392	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—ESR1—urinary bladder cancer	3.29e-05	0.000392	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.2e-05	0.000381	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.19e-05	0.00038	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.18e-05	0.000378	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—ESR2—urinary bladder cancer	3.14e-05	0.000373	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.14e-05	0.000373	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.13e-05	0.000373	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.08e-05	0.000366	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.07e-05	0.000365	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.07e-05	0.000365	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.07e-05	0.000365	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—S100B—urinary bladder cancer	3.03e-05	0.00036	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—PPARG—urinary bladder cancer	3e-05	0.000357	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.92e-05	0.000348	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.91e-05	0.000346	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.9e-05	0.000345	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.89e-05	0.000344	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—CREBBP—urinary bladder cancer	2.88e-05	0.000343	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PTEN—urinary bladder cancer	2.87e-05	0.000342	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.83e-05	0.000337	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—MYC—urinary bladder cancer	2.81e-05	0.000334	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—NQO1—urinary bladder cancer	2.79e-05	0.000332	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.77e-05	0.00033	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ENO2—urinary bladder cancer	2.76e-05	0.000328	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—EP300—urinary bladder cancer	2.74e-05	0.000326	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	2.72e-05	0.000324	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.7e-05	0.000322	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.68e-05	0.000319	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.67e-05	0.000318	CbGpPWpGaD
Betamethasone—PTGS2—Disease—RBX1—urinary bladder cancer	2.61e-05	0.000311	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.57e-05	0.000306	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.55e-05	0.000303	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.49e-05	0.000297	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.48e-05	0.000295	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.43e-05	0.000289	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	2.42e-05	0.000288	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TERT—urinary bladder cancer	2.4e-05	0.000286	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.36e-05	0.000281	CbGpPWpGaD
Betamethasone—PTGS2—Disease—JAG1—urinary bladder cancer	2.34e-05	0.000278	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	2.32e-05	0.000277	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.31e-05	0.000275	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.31e-05	0.000275	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.3e-05	0.000274	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.3e-05	0.000274	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.3e-05	0.000273	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	2.28e-05	0.000271	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.26e-05	0.000269	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.25e-05	0.000268	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.24e-05	0.000267	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.22e-05	0.000264	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.21e-05	0.000262	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	2.2e-05	0.000262	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.17e-05	0.000259	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—TYMS—urinary bladder cancer	2.16e-05	0.000257	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ESR1—urinary bladder cancer	2.14e-05	0.000255	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	2.14e-05	0.000254	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	2.14e-05	0.000254	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.11e-05	0.000251	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.07e-05	0.000246	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.05e-05	0.000245	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.05e-05	0.000244	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.05e-05	0.000244	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GPX1—urinary bladder cancer	2.04e-05	0.000243	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	2.01e-05	0.000239	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—ESR1—urinary bladder cancer	1.9e-05	0.000226	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.9e-05	0.000226	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	1.89e-05	0.000225	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	1.88e-05	0.000223	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.86e-05	0.000222	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IGF1—urinary bladder cancer	1.85e-05	0.00022	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.82e-05	0.000217	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.79e-05	0.000213	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.77e-05	0.00021	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.75e-05	0.000208	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PPARG—urinary bladder cancer	1.74e-05	0.000207	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—MYC—urinary bladder cancer	1.71e-05	0.000204	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NCOR1—urinary bladder cancer	1.7e-05	0.000203	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—RHOA—urinary bladder cancer	1.7e-05	0.000202	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	1.67e-05	0.000198	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.64e-05	0.000195	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.64e-05	0.000195	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ERCC2—urinary bladder cancer	1.6e-05	0.000191	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.59e-05	0.000189	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.58e-05	0.000187	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	1.57e-05	0.000187	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.55e-05	0.000185	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PPARG—urinary bladder cancer	1.53e-05	0.000182	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MTHFR—urinary bladder cancer	1.51e-05	0.000179	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.5e-05	0.000179	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TERT—urinary bladder cancer	1.5e-05	0.000179	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	1.49e-05	0.000177	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.49e-05	0.000177	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	1.47e-05	0.000175	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.44e-05	0.000172	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.43e-05	0.00017	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.43e-05	0.00017	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IL2—urinary bladder cancer	1.42e-05	0.000169	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.4e-05	0.000166	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CCND1—urinary bladder cancer	1.39e-05	0.000165	CbGpPWpGaD
Betamethasone—PTGS2—Disease—FGFR3—urinary bladder cancer	1.38e-05	0.000164	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.37e-05	0.000163	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MMP9—urinary bladder cancer	1.35e-05	0.00016	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.34e-05	0.00016	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.34e-05	0.00016	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PTEN—urinary bladder cancer	1.34e-05	0.000159	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.32e-05	0.000157	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—EP300—urinary bladder cancer	1.28e-05	0.000152	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.26e-05	0.00015	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.26e-05	0.00015	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SRC—urinary bladder cancer	1.24e-05	0.000148	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	1.2e-05	0.000143	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CREBBP—urinary bladder cancer	1.17e-05	0.00014	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MYC—urinary bladder cancer	1.11e-05	0.000132	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.1e-05	0.000131	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.09e-05	0.00013	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-05	0.00013	CbGpPWpGaD
Betamethasone—PTGS2—Disease—RHOA—urinary bladder cancer	1.06e-05	0.000126	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PTEN—urinary bladder cancer	1.05e-05	0.000125	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	0.000122	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.02e-05	0.000122	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.02e-05	0.000122	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.01e-05	0.00012	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.01e-05	0.00012	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.01e-05	0.00012	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.01e-05	0.00012	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—EP300—urinary bladder cancer	1e-05	0.000119	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—MYC—urinary bladder cancer	9.89e-06	0.000118	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CREBBP—urinary bladder cancer	9.82e-06	0.000117	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ERBB2—urinary bladder cancer	9.82e-06	0.000117	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.78e-06	0.000116	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.69e-06	0.000115	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.51e-06	0.000113	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TP53—urinary bladder cancer	9.14e-06	0.000109	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.94e-06	0.000106	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—HRAS—urinary bladder cancer	8.74e-06	0.000104	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CDKN1A—urinary bladder cancer	8.4e-06	9.99e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PTEN—urinary bladder cancer	8.38e-06	9.97e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.13e-06	9.68e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—EP300—urinary bladder cancer	7.99e-06	9.51e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—SRC—urinary bladder cancer	7.77e-06	9.24e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.25e-06	8.63e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PTEN—urinary bladder cancer	7.02e-06	8.35e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.96e-06	8.29e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MYC—urinary bladder cancer	6.96e-06	8.28e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—EGFR—urinary bladder cancer	6.81e-06	8.1e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.78e-06	8.07e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—EP300—urinary bladder cancer	6.69e-06	7.96e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—KRAS—urinary bladder cancer	6.43e-06	7.65e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.3e-06	7.5e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.23e-06	7.42e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.23e-06	7.42e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.97e-06	7.1e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.86e-06	6.97e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.7e-06	6.79e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.51e-06	6.55e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HRAS—urinary bladder cancer	5.47e-06	6.51e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.97e-06	5.92e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—EP300—urinary bladder cancer	4.74e-06	5.64e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.47e-06	5.31e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.29e-06	5.11e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.51e-06	4.18e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.06e-06	3.65e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.92e-06	3.48e-05	CbGpPWpGaD
